The Chemours Company (NYSE:CC - Free Report) - Analysts at Zacks Research lowered their FY2026 earnings estimates for Chemours in a research report issued to clients and investors on Monday, November 16th. Zacks Research analyst Team now expects that the specialty chemicals company will post earnings per share of $0.73 for the year, down from their prior forecast of $0.83. Zacks Research has a "Strong Sell" rating on the stock. The consensus estimate for Chemours' current full-year earnings is $0.82 per share. Zacks Research also issued estimates for Chemours' Q4 2026 earnings at $0.05 EPS, Q3 2027 earnings at $0.51 EPS, Q4 2027 earnings at $0.52 EPS, Q1 2028 earnings at $0.44 EPS, Q2 2028 earnings at $0.59 EPS and Q3 2028 earnings at $0.42 EPS.
A number of other research analysts have also recently issued reports on the company. BMO Capital Markets decreased their target price on Chemours from $26.00 to $18.00 and set an "outperform" rating on the stock in a research report on Thursday, August 13th. JPMorgan Chase & Co. lowered their target price on Chemours from $15.00 to $14.00 and set a "neutral" rating for the company in a research note on Monday, November 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of Chemours in a report on Tuesday, November 3rd. Mizuho downgraded shares of Chemours from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $18.00 to $15.00 in a research note on Wednesday, October 14th. Finally, Barclays began coverage on shares of Chemours in a report on Monday, October 12th. They set an "equal weight" rating and a $16.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $17.36.
Get Our Latest Stock Report on CC
Chemours Price Performance
Chemours stock opened at $12.45 on Tuesday. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67. The stock has a market capitalization of $1.87 billion, a P/E ratio of -12.20 and a beta of 1.47. The stock has a fifty day moving average of $13.69 and a 200-day moving average of $18.14.
Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The firm had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the prior year, the firm earned $0.40 earnings per share. The firm's revenue for the quarter was up 3.0% on a year-over-year basis.
Institutional Investors Weigh In On Chemours
Several hedge funds have recently modified their holdings of the company. Deutsche Bank AG bought a new stake in shares of Chemours during the second quarter worth about $3,291,000. The Manufacturers Life Insurance Company acquired a new position in shares of Chemours in the second quarter valued at approximately $1,522,000. BlackRock Inc. acquired a new position in shares of Chemours in the second quarter valued at approximately $477,769,000. Jefferies Financial Group Inc. bought a new position in Chemours in the 2nd quarter valued at approximately $15,996,000. Finally, Old West Investment Management LLC bought a new position in Chemours in the 2nd quarter valued at approximately $7,152,000. Institutional investors and hedge funds own 76.26% of the company's stock.
Chemours Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, November 16th. Chemours's dividend payout ratio is presently -34.31%.
Key Headlines Impacting Chemours
Here are a few of the latest headlines about CC:
- Negative Sentiment: Analyst estimates were cut: Zacks Research lowered its forecasts for several quarters through 2028, including FY2026 EPS to $0.73 from $0.83 and Q4 2026 EPS to $0.05 from $0.11. The firm also rates Chemours “Strong Sell,” reinforcing concerns about its earnings outlook.
- Negative Sentiment: Class-action litigation adds uncertainty: Shareholder lawsuits allege Chemours and some executives misrepresented Opteon demand. The claims relate to a reported 18.63% share decline following reduced 2026 guidance and concerns about an oversupplied refrigerant channel; the allegations have not been proven. Article: Chemours Investors Sued for Securities Fraud
- Negative Sentiment: Investors face a December 7 lead-plaintiff deadline: Multiple law firms publicized the pending case and encouraged investors to seek lead-plaintiff status, keeping the allegations in the spotlight. Article: Chemours Securities Class-Action Deadline
About Chemours
(
Get Free Report)
The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours' Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chemours, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.
While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.